Imugene (IUGNF) AI Stock Analysis

40 Followers

Imugene

(Other OTC:IUGNF)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Low LeverageRelatively low leverage provides some financial flexibility compared with a more heavily indebted biotech. Modest debt versus assets can reduce fixed financing pressure and leave the company better positioned to direct available capital toward research, trials, and other development priorities.

Negative Factors

Revenue ContractionMaterially declining revenue and zero annual revenue indicate that the business is not currently supported by a dependable commercial income stream. This limits internal funding capacity, increases reliance on capital raising or partnerships, and makes near-term progress dependent on successful development execution.

Imugene (IUGNF) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $21.43M
Dividend Yield: ―
Average Volume (3M): 36.55K
Price to Earnings (P/E): -0.1
Beta (1Y): -1.09
Revenue Growth: ―
EPS Growth: -6.92%
Country: US
Employees: 14
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Imugene Business Overview & Revenue Model

Company Description

Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic C...

Imugene Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

IUGNF against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AU:TLX	53Neutral	AUD 4.70B	97.04	7.24%	―	26.66%	179.32%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AU:CU6	41Neutral	AUD 619.31M	-6.69	-51.15%	―	―	-44.83%
AU:NOX	38Underperform	AUD 12.36M	-2.29	186.62%	―	―	10.18%
AU:IMM	38Underperform	AUD 35.38M	-0.46	-98.86%	―	―	-27.73%
AU:PTX	37Underperform	AUD 68.63M	-9.13	-44.93%	―	―	25.27%

* Healthcare Sector Average

Performance Comparison

IUGNF and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IUGNF	Imugene Ltd	0.04	-0.16	-80.50%
AU:IMM	Immutep Ltd	0.03	-0.24	-90.38%
AU:PTX	Prescient Therapeutics Limited	0.06	0.01	29.17%
AU:TLX	Telix Pharmaceuticals Ltd.	14.02	-0.96	-6.41%
AU:NOX	Noxopharm Ltd.	0.04	-0.06	-62.11%
AU:CU6	Clarity Pharmaceuticals Ltd.	1.66	-2.40	-59.11%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Imugene AI Stock Analysis